Projects

Basic SCIENCE

  1. Revealing the mode of resistance in non-small-cell lung cancer cell lines to targeted therapies of the EGFR pathway by proteome analyses and genomic profiling
    • Non Small Cell Lung Cancer (NSCLC)
    • EGFR -pathway Inhibitors
    • AIM: testing of resistance mechanisms and synergistic effects of targeting drugs
    • STATUS:ongoing
  2. Proteome changes in colorectal cell lines under treatment with tyrosine kinase inhibitors
    • Colorectal Carcinoma (CRC)
    • Tyrosine Kinase Inhibitors
    • AIM: protein profiles and changes caused by sorafenib
    • STATUS: ongoing
  3. Direct and indirect effects of recombinant mistletoe lectine on colorectal and non-small-cell lung cancer cell lines
    • Colorectal Cancer (CRC) and Non-Small-Cell Lung Cancer (NSCLC)
      Recombinant miste etoe lectine
      AIM: direct cytotoxic effects (changes of genetic and protein levels) and influence on ADCC of NK and cytotoxic T -cells
      STATUS: ongoing
  4. Proteasome inhibitor bortezomib -definition of regulated proteins
    • Colorectal Cancer (CRC) and Non-Small-Cell Lung Cancer (NSCLC)
    • Bortezomib
    • AIM: mechanisms of resistance and action of Bortezomib
    • Status: finished

Clinical SCIENCE

  1. INN06 -STUDY
    • Non Small Cell Lung Cancer (NSCLC)
    • Phase II trial
    • Neoadjuvant Cetuximab + Cisplatin + Docetaxel
    • AIM: Toxcicity, Testing of resistance mechanisms (qPCR for resistance related genes, IHC), Immunological effects (Treg testing)
    • STATUS:Ongoing
  2. TEXO 0309
    • Head and Neck Cancer (SCCNH), Colorectal Carcinoma (CRC), Non Small Cell Lung Cancer (NSCLC)
    • Phase I trial
    • Lenalidomide + Cetuximab
    • AIM: Toxcicity, Gene and protein profiles and changes, Immunological effects (ADCC, T-Cell Subsets, CKs/ILs)
    • STATUS: Ongoing
  3. TEXO 0310
    • Colorectal Carcinoma (CRC)
    • ransomised Phase II Trial
    • recombinant Mistel lectine
    • AIM: Efficacy, Immunological effects
    • STATUS:Pending
© 2009 by TEXO – Tyrolean Working Group of Experimental Oncology